Damora Therapeutics, Inc. (DMRA) stock
DMRANasdaqPharmaceutical PreparationsFiscal year ends December 31
$22.56+0.06 (+0.29%)
Close on Nov 17, 2026Market cap $1.39BP/E 5.7Yield 0.00%
Damora Therapeutics r&d expenses
Research and development expenses are spending on new products and technology.
Damora Therapeutics's R&D Expenses for the twelve months ending Sep 30, 2026 was $98.11M, up 2048.2% year over year. For fiscal 2025 it was $26.88M, up 320.1% from the year before. The highest annual figure on record is $48.21M in fiscal 2022.
Annual r&d expenses
| Period | Period end | Value | Change |
|---|---|---|---|
| FY2025 | Dec 31, 2025 | $26.88M | +320.1% |
| FY2024 | Dec 31, 2024 | $6.40M | -73.1% |
| FY2023 | Dec 31, 2023 | $23.77M | -50.7% |
| FY2022 | Dec 31, 2022 | $48.21M | +25.2% |
| FY2021 | Dec 31, 2021 | $38.49M | +56.3% |
| FY2020 | Dec 31, 2020 | $24.63M | +24.8% |
| FY2019 | Dec 31, 2019 | $19.74M | – |
Quarterly r&d expenses
Change is against the same quarter a year earlier.
| Period | Period end | Value | Change |
|---|---|---|---|
| Q3 FY2026 | Sep 30, 2026 | $25.48M | +1699.1% |
| Q2 FY2026 | Jun 30, 2026 | $25.54M | +1643.3% |
| Q1 FY2026 | Mar 31, 2026 | $23.78M | +3406.9% |
| Q4 FY2025 | Dec 31, 2025 | $23.32M | +2213.3% |
| Q3 FY2025 | Sep 30, 2025 | $1.42M | +29.6% |
| Q2 FY2025 | Jun 30, 2025 | $1.47M | -20.1% |
| Q1 FY2025 | Mar 31, 2025 | $678.00K | -72.5% |
| Q4 FY2024 | Dec 31, 2024 | $1.01M | -63.6% |
| Q3 FY2024 | Sep 30, 2024 | $1.09M | -57.2% |
| Q2 FY2024 | Jun 30, 2024 | $1.83M | -77.3% |
| Q1 FY2024 | Mar 31, 2024 | $2.46M | -76.2% |
| Q4 FY2023 | Dec 31, 2023 | $2.77M | -74.3% |
| Q3 FY2023 | Sep 30, 2023 | $2.55M | -75.7% |
| Q2 FY2023 | Jun 30, 2023 | $8.09M | -41.0% |
| Q1 FY2023 | Mar 31, 2023 | $10.36M | -21.7% |
| Q4 FY2022 | Dec 31, 2022 | $10.77M | +6.5% |
| Q3 FY2022 | Sep 30, 2022 | $10.49M | +7.7% |
| Q2 FY2022 | Jun 30, 2022 | $13.71M | +58.7% |
| Q1 FY2022 | Mar 31, 2022 | $13.24M | +32.5% |
| Q4 FY2021 | Dec 31, 2021 | $10.12M | +30.5% |
| Q3 FY2021 | Sep 30, 2021 | $9.75M | +27.4% |
| Q2 FY2021 | Jun 30, 2021 | $8.64M | +91.3% |
| Q1 FY2021 | Mar 31, 2021 | $9.99M | +112.2% |
| Q4 FY2020 | Dec 31, 2020 | $7.75M | -1.2% |
| Q3 FY2020 | Sep 30, 2020 | $7.65M | +108.2% |
| Q2 FY2020 | Jun 30, 2020 | $4.52M | – |
| Q1 FY2020 | Mar 31, 2020 | $4.71M | – |
| Q4 FY2019 | Dec 31, 2019 | $7.85M | – |
| Q3 FY2019 | Sep 30, 2019 | $3.67M | – |
See a number that looks wrong?